These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 12930139)

  • 1. Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.
    Wu YJ; Davis CD; Dworetzky S; Fitzpatrick WC; Harden D; He H; Knox RJ; Newton AE; Philip T; Polson C; Sivarao DV; Sun LQ; Tertyshnikova S; Weaver D; Yeola S; Zoeckler M; Sinz MW
    J Med Chem; 2003 Aug; 46(18):3778-81. PubMed ID: 12930139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (S)-N-[1-(3-morpholin-4-ylphenyl)ethyl]- 3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine.
    Wu YJ; Boissard CG; Greco C; Gribkoff VK; Harden DG; He H; L'Heureux A; Kang SH; Kinney GG; Knox RJ; Natale J; Newton AE; Lehtinen-Oboma S; Sinz MW; Sivarao DV; Starrett JE; Sun LQ; Tertyshnikova S; Thompson MW; Weaver D; Wong HS; Zhang L; Dworetzky SI
    J Med Chem; 2003 Jul; 46(15):3197-200. PubMed ID: 12852750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationship of acrylamides as KCNQ2 potassium channel openers.
    Wu YJ; He H; Sun LQ; L'Heureux A; Chen J; Dextraze P; Starrett JE; Boissard CG; Gribkoff VK; Natale J; Dworetzky SI
    J Med Chem; 2004 May; 47(11):2887-96. PubMed ID: 15139767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (S)-N-[1-(4-cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)-acrylamide is a potent and efficacious KCNQ2 opener which inhibits induced hyperexcitability of rat hippocampal neurons.
    Wu YJ; Boissard CG; Chen J; Fitzpatrick W; Gao Q; Gribkoff VK; Harden DG; He H; Knox RJ; Natale J; Pieschl RL; Starrett JE; Sun LQ; Thompson M; Weaver D; Wu D; Dworetzky SI
    Bioorg Med Chem Lett; 2004 Apr; 14(8):1991-5. PubMed ID: 15050644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (S,E)-N-[1-(3-heteroarylphenyl)ethyl]-3-(2-fluorophenyl)acrylamides: synthesis and KCNQ2 potassium channel opener activity.
    L'Heureux A; Martel A; He H; Chen J; Sun LQ; Starrett JE; Natale J; Dworetzky SI; Knox RJ; Harden DG; Weaver D; Thompson MW; Wu YJ
    Bioorg Med Chem Lett; 2005 Jan; 15(2):363-6. PubMed ID: 15603955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and KCNQ2 opener activity of N-(1-benzo[1,3]dioxol-5-yl-ethyl, N-[1-(2,3-dihydro-benzofuran-5-yl)-ethyl, and N-[1-(2,3-dihydro-1H-indol-5-yl)-ethyl acrylamides.
    Wu YJ; Sun LQ; He H; Chen J; Starrett JE; Dextraze P; Daris JP; Boissard CG; Pieschl RL; Gribkoff VK; Natale J; Knox RJ; Harden DG; Thompson MW; Fitzpatrick W; Weaver D; Wu D; Gao Q; Dworetzky SI
    Bioorg Med Chem Lett; 2004 Sep; 14(17):4533-7. PubMed ID: 15357987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of (S,E)-3-(2-fluorophenyl)-N-(1-(3-(pyridin-3-yloxy)phenyl)ethyl)-acrylamide as a potent and efficacious KCNQ2 (Kv7.2) opener for the treatment of neuropathic pain.
    Wu YJ; Conway CM; Sun LQ; Machet F; Chen J; Chen P; He H; Bourin C; Calandra V; Polino JL; Davis CD; Heman K; Gribkoff VK; Boissard CG; Knox RJ; Thompson MW; Fitzpatrick W; Weaver D; Harden DG; Natale J; Dworetzky SI; Starrett JE
    Bioorg Med Chem Lett; 2013 Nov; 23(22):6188-91. PubMed ID: 24070783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidation mechanism in the metabolism of (S)-N-[1-(3-morpholin-4-ylphenyl)ethyl]-3-phenylacrylamide on oxyferryl active site in CYP3A4 Cytochrome: DFT modeling.
    Shaikh AR; Broclawik E; Tsuboi H; Koyama M; Endou A; Takaba H; Kubo M; Del Carpio CA; Miyamoto A
    J Mol Model; 2007 Jul; 13(6-7):851-60. PubMed ID: 17387527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels.
    Bentzen BH; Schmitt N; Calloe K; Dalby Brown W; Grunnet M; Olesen SP
    Neuropharmacology; 2006 Nov; 51(6):1068-77. PubMed ID: 16904708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ionic permeation and conduction properties of neuronal KCNQ2/KCNQ3 potassium channels.
    Prole DL; Marrion NV
    Biophys J; 2004 Mar; 86(3):1454-69. PubMed ID: 14990473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator.
    Wickenden AD; Krajewski JL; London B; Wagoner PK; Wilson WA; Clark S; Roeloffs R; McNaughton-Smith G; Rigdon GC
    Mol Pharmacol; 2008 Mar; 73(3):977-86. PubMed ID: 18089837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637): a novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. I. In vitro characterization.
    Gopalakrishnan M; Buckner SA; Whiteaker KL; Shieh CC; Molinari EJ; Milicic I; Daza AV; Davis-Taber R; Scott VE; Sellers D; Chess-Williams R; Chapple CR; Liu Y; Liu D; Brioni JD; Sullivan JP; Williams M; Carroll WA; Coghlan MJ
    J Pharmacol Exp Ther; 2002 Oct; 303(1):379-86. PubMed ID: 12235274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP3A4 inhibitory activity of new bisalkaloids, dipiperamides D and E, and cognates from white pepper.
    Tsukamoto S; Tomise K; Miyakawa K; Cha BC; Abe T; Hamada T; Hirota H; Ohta T
    Bioorg Med Chem; 2002 Sep; 10(9):2981-5. PubMed ID: 12110320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Arylated pyrrolidin-2-ones and morpholin-3-ones as potassium channel openers.
    Liang PH; Hsin LW; Cheng CY
    Bioorg Med Chem; 2002 Oct; 10(10):3267-76. PubMed ID: 12150872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-terminal interaction of KCNQ2 and KCNQ3 K+ channels.
    Maljevic S; Lerche C; Seebohm G; Alekov AK; Busch AE; Lerche H
    J Physiol; 2003 Apr; 548(Pt 2):353-60. PubMed ID: 12640002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The synthesis and structure-activity relationships of 3-amino-4-benzylquinolin-2-ones; discovery of novel KCNQ2 channel openers.
    Hewawasam P; Chen N; Ding M; Natale JT; Boissard CG; Yeola S; Gribkoff VK; Starrett J; Dworetzky SI
    Bioorg Med Chem Lett; 2004 Apr; 14(7):1615-8. PubMed ID: 15026035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a potent, orally bioavailable and highly selective human neuronal nitric oxide synthase (nNOS) inhibitor, N-(1-(piperidin-4-yl)indolin-5-yl)thiophene-2-carboximidamide as a pre-clinical development candidate for the treatment of migraine.
    Annedi SC; Maddaford SP; Ramnauth J; Renton P; Rybak T; Silverman S; Rakhit S; Mladenova G; Dove P; Andrews JS; Zhang D; Porreca F
    Eur J Med Chem; 2012 Sep; 55():94-107. PubMed ID: 22840695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphatidylinositol-4,5-bisphosphate, PIP2, controls KCNQ1/KCNE1 voltage-gated potassium channels: a functional homology between voltage-gated and inward rectifier K+ channels.
    Loussouarn G; Park KH; Bellocq C; Baró I; Charpentier F; Escande D
    EMBO J; 2003 Oct; 22(20):5412-21. PubMed ID: 14532114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calmodulin mediates Ca2+-dependent modulation of M-type K+ channels.
    Gamper N; Shapiro MS
    J Gen Physiol; 2003 Jul; 122(1):17-31. PubMed ID: 12810850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voltage-gated potassium channels activated during action potentials in layer V neocortical pyramidal neurons.
    Kang J; Huguenard JR; Prince DA
    J Neurophysiol; 2000 Jan; 83(1):70-80. PubMed ID: 10634854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.